Company profile
CG ONCOLOGY, INC.
NASDAQ:CGONBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CRETOSTIMOGENE GRENADENOREPVEC | phase3 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06111235 | phase3 | active_not_recruiting | 2023-12-14 | 2026-11-01 | CG Oncology, Inc. | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT |
| NCT01438112 | phase2_3 | terminated | 2014-03-01 | 2016-06-01 | CG Oncology, Inc. | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer |
| NCT06567743 | phase2 | recruiting | 2024-09-16 | 2027-03-31 | CG Oncology, Inc. | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC |
| NCT02365818 | phase2 | completed | 2015-06-02 | 2018-08-01 | CG Oncology, Inc. | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure |
| NCT02143804 | phase2 | withdrawn | 2014-03-01 | 2015-03-01 | CG Oncology, Inc. | Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer |
FDA applications (0)
No records yet.